| Dr Laura Klatt House, MD | |
|
4420 Lake Boone Trl, Raleigh, NC 27607-7505 | |
| (919) 364-3312 | |
| Not Available |
| Full Name | Dr Laura Klatt House |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 4420 Lake Boone Trl, Raleigh, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164559829 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2008-01194 (North Carolina) | Secondary |
| 207Q00000X | Family Medicine | 2008-01194 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Chatham Hospital Inc | Siler city, NC | Hospital |
| Rex Hospital | Raleigh, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians And Associates | 0648181156 | 1656 |
| Rex Hospital Inc | 0840109864 | 652 |
| Chatham Hospital Inc | 4284807868 | 57 |
News Archive
People with severe Parkinson's disease or other neurological conditions that cause intractable symptoms such as uncontrollable shaking, muscle spasms, seizures, obsessive thoughts and compulsive behaviors are sometimes treated with electric stimulators placed inside the brain.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Ever wonder why some people seem to feel less pain than others? A study conducted at Wake Forest School of Medicine may have found one of the answers – mindfulness.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
› Verified 1 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
People with severe Parkinson's disease or other neurological conditions that cause intractable symptoms such as uncontrollable shaking, muscle spasms, seizures, obsessive thoughts and compulsive behaviors are sometimes treated with electric stimulators placed inside the brain.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Ever wonder why some people seem to feel less pain than others? A study conducted at Wake Forest School of Medicine may have found one of the answers – mindfulness.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
› Verified 1 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1093712655 PECOS PAC ID: 5991604902 Enrollment ID: O20061104000243 |
News Archive
People with severe Parkinson's disease or other neurological conditions that cause intractable symptoms such as uncontrollable shaking, muscle spasms, seizures, obsessive thoughts and compulsive behaviors are sometimes treated with electric stimulators placed inside the brain.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Ever wonder why some people seem to feel less pain than others? A study conducted at Wake Forest School of Medicine may have found one of the answers – mindfulness.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
› Verified 1 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689967457 PECOS PAC ID: 4284807868 Enrollment ID: O20111026000545 |
News Archive
People with severe Parkinson's disease or other neurological conditions that cause intractable symptoms such as uncontrollable shaking, muscle spasms, seizures, obsessive thoughts and compulsive behaviors are sometimes treated with electric stimulators placed inside the brain.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Ever wonder why some people seem to feel less pain than others? A study conducted at Wake Forest School of Medicine may have found one of the answers – mindfulness.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
› Verified 1 days ago
| Entity Name | Rex Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144248683 PECOS PAC ID: 0840109864 Enrollment ID: O20140613001181 |
News Archive
People with severe Parkinson's disease or other neurological conditions that cause intractable symptoms such as uncontrollable shaking, muscle spasms, seizures, obsessive thoughts and compulsive behaviors are sometimes treated with electric stimulators placed inside the brain.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Ever wonder why some people seem to feel less pain than others? A study conducted at Wake Forest School of Medicine may have found one of the answers – mindfulness.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura Klatt House, MD Cb# 7595 Us 15-501 And Manning Dr., Unc Family Medicine Center, Chapel Hill, NC 27599-7595 Ph: (919) 966-0210 | Dr Laura Klatt House, MD 4420 Lake Boone Trl, Raleigh, NC 27607-7505 Ph: (919) 364-3312 |
News Archive
People with severe Parkinson's disease or other neurological conditions that cause intractable symptoms such as uncontrollable shaking, muscle spasms, seizures, obsessive thoughts and compulsive behaviors are sometimes treated with electric stimulators placed inside the brain.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.
Ever wonder why some people seem to feel less pain than others? A study conducted at Wake Forest School of Medicine may have found one of the answers – mindfulness.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
› Verified 1 days ago
Conrad Flick, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3500 Bush St, Raleigh, NC 27609 Phone: 919-875-8150 Fax: 919-875-9577 | |
Dr. Christopher Zaguirre Rayala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 150 E Davie St, Raleigh, NC 27601 Phone: 919-834-5299 | |
Dr. Mona Soliman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11200 Governor Manly Way, Raleigh, NC 27614 Phone: 919-570-7700 | |
Douglas Ira Hammer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1207 Watauga St, Raleigh, NC 27604 Phone: 919-215-5078 | |
William Grant Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11200 Governor Manly Way, Raleigh, NC 27614 Phone: 919-747-5270 Fax: 919-747-5271 | |
Mrs. Soenda P Norman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10211 Alm St, Suite 1200, Raleigh, NC 27617 Phone: 919-206-4889 Fax: 919-206-4875 | |
Dr. Jason Troiano, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Donald Ross Dr, Raleigh, NC 27610 Phone: 919-250-3320 |